Shots:
- Sunovion to receive $270M up front, $620M as development milestone for 4 candidates & is also eligible to receive sales milestone. Sunovion & Otsuka will share profits & expenses for clinical studies, applications for approval, & commercialization in each licensed territories
- Otsuka gets the rights from Sunovion to jointly develop & commercialize 4 compounds globally i.e., ulotaront (SEP-363856), SEP-4199, SEP-378614 & SEP-380135 to treat neuropsychiatric disorders
- Sumitomo Dainippon Pharma & Otsuka plan to co-promote 4 candidates jointly where Sumitomo Dainippon will record sales in the US, Canada, Japan & Asia. Otsuka will record sales in 41 other countries and regions including the EU
Click here to read full press release/ article | Ref: Otsuka | Image: Wikipedia
The post Otsuka Enters into a WW License Agreement with Sunovion and Sumitomo Dainippon to Develop and Commercialize Neuropsychiatric Candidates first appeared on PharmaShots.
